13F Pro13F Pro

Spruce Street Capital LP

Institutional InvestorSimilar funds →SEC EDGAR: CIK 2050194
Institutional-grade research for retail investors

Sector Allocation

  • Healthcare97.5%$497.2M
  • Financials1.4%$7.2M
  • Other1.0%$5.3M

AUM History

13fpro.ai/research/fund/spruce-street-capital-lp-2050194

Conviction and streaks

Concentrating · top 10 = 70.2%

From the fund's last 12 quarters of 13F filings: positions held longest at size, and names it added to or trimmed several quarters running.

KNSA$KNSAAccumulating+111% shares · 2 quarters runningRLMD$RLMDAccumulating+56% shares · 2 quarters runningANRO$ANROAccumulating+507% shares · 2 quarters runningSVRA$SVRAAccumulating+43% shares · 2 quarters runningENTA$ENTAAccumulating+179% shares · 2 quarters running

Largest positions — Q2 2026

Top 20 stock positions. Options are left out: 13F reports them at the underlying's value.

13fpro.ai/research/fund/spruce-street-capital-lp-2050194

Spruce Street Capital LP 13F holdings — Q2 2026

$509.7M portfolio (+22.5% QoQ) · 30 holdings · Q2 2026 13F · top 10 are 70% of the stock portfolio

All holdings — Spruce Street Capital LP (Q2 2026)

30 disclosed positions from the Form 13F-HR on SEC EDGAR, with quarter-over-quarter share changes. Largest by value first; the ten above are not repeated.

Company
ENTA$ENTAENANTA PHARMACEUTICALS INC$15.9M+17%
CATX$CATXPerspective Therapeutics, Inc.$12.6M+41%
IFRX$IFRXInflaRx N.V.$12.0MNew
SRZN$SRZNSurrozen, Inc./DE$11.2M—
ALMS$ALMSALUMIS INC.$11.0M—
IPSC$IPSCCentury Therapeutics, Inc.$9.9M—
NERV$NERVMinerva Neurosciences, Inc.$9.2M—
SABS$SABSSAB Biotherapeutics, Inc.$8.6M—
ANTX$ANTXAN2 Therapeutics, Inc.$8.0M—
ERAS$ERASErasca, Inc.$7.7M—
IKT$IKTInhibikase Therapeutics, Inc.$7.3M—
RACC$RACCResearch Alliance Corp III$5.3MNew
— HELIX ACQUISITION CORP III - USD CL A ORD SHS$5.3M—
ZLAB$ZLABZai Lab Ltdadr$5.3MNew
ACHV$ACHVACHIEVE LIFE SCIENCES, INC.$4.8MNew

What changed in Q2 2026

Against the previous quarter's 13F: 5 new, 8 added to, 1 trimmed, 3 sold out. Share-count changes; largest moves by dollar size first.

New positions (5)

  • IFRX$IFRXInflaRx N.V.$12.0M

    first bought this quarter

  • RACC$RACCResearch Alliance Corp III$5.3M

    first bought this quarter

  • ZLAB$ZLABZai Lab Ltd$5.3M

    first bought this quarter

  • ACHV$ACHVACHIEVE LIFE SCIENCES, INC.$4.8M

    first bought this quarter

  • JATT$JATTJATT II Acquisition Corp.$1.8M

    first bought this quarter

Added to (8)

  • ALKS$ALKSAlkermes plc.+71%

    now $28.5M · held 2 qtrs, 2 adds in a row

  • KNSA$KNSAKiniksa Pharmaceuticals International, plc+21%

    now $58.7M · held 3+ qtrs, 2 adds in a row

  • CATX$CATXPerspective Therapeutics, Inc.+41%

    now $12.6M · held 2 qtrs, 2 adds in a row

  • PCVX$PCVXVaxcyte, Inc.+25%

    now $17.8M · held 3+ qtrs

  • ENTA$ENTAENANTA PHARMACEUTICALS INC+17%

    now $15.9M · held 3+ qtrs, 2 adds in a row

  • RLMD$RLMDRELMADA THERAPEUTICS, INC.+2%

    now $44.2M · held 3+ qtrs, 2 adds in a row

+2 more in the Excel export

Trimmed (1)

  • DNTH$DNTHDianthus Therapeutics, Inc. /DE/-5%

    now $34.6M · held 3+ qtrs

Sold out (3)

  • CNTA$CNTACentessa Pharmaceuticals plcwas $19.5M

    held 2+ qtrs

  • KALV$KALVKalVista Pharmaceuticals, Inc.was $18.1M

    held 2+ qtrs

  • MAZE$MAZEMaze Therapeutics, Inc.was $6.0M

    held 1 qtr

Firm AUM (Form ADV): $555.9M as of 2025-12-31 · SEC IAPD

Share

Holdings by quarter

Every 13F Spruce Street Capital LP has filed, 2 earlier quarters. Pick one to see what it held then.

Email me the moment this fund files its next 13FPro

Is it too late to follow Spruce Street Capital?

Q2 2026 13F filed with the SEC on Aug 13, 2026. Prices are closing prices as of Oct 26, 2026.

Average quality of Spruce Street Capital's top 20 holdings: 26/100 (our AI quality score, weighted by position size; 5 of the 20 are scored)

Top 10 since filing

-16.5%

Value-weighted move of the 10 largest stock positions

Turnover

10%

Last quarter

Top 10 weight

70%

Share of the stock portfolio in its 10 largest positions

Held 4+ quarters

0%

Share of portfolio value in positions held a year or more

Highest-quality names it owns(among its 100 largest positions)

The 6 highest-scoring companies in this portfolio are a Pro feature.

How these are measured
  • Moves since the quarter-end and since the filing date use our own daily closing prices, from the close on (or just before) each date to the latest close.
  • Turnover is the lesser of shares bought or sold in a quarter, valued at the quarter-end prices in the 13F, divided by the average of the two quarters' stock portfolio values.
  • Quarters held and add/trim streaks count back only through quarters whose filed holdings add up to the filing's own cover-page total (back to Q4 2025 for this fund). A change counts as an add or a trim when the split-adjusted share count moves by more than 1%.
  • Estimate, not the fund's reported cost. For each quarter in the current holding period in which the fund's share count rose (split-adjusted), we take that quarter's average daily close and weight it by the shares added; sales do not change an average cost. Quarters where the stock's price history and the 13F's own implied price disagree by more than 2x are left out.
  • Put and call option rows report the value of the underlying shares, not a position the fund paid for, so they are left out of all of the above.

Portfolio Overview

Spruce Street Capital LP disclosed 30 positions worth $509.7M in its Form 13F-HR for Q2 2026, led by $KNSA (Kiniksa Pharmaceuticals International, plc) at 11.5% of the equity portfolio, followed by $RLAY and $LBRX. During the quarter the fund opened 5 new positions and exited 3 — including a new stake in $IFRX and a full exit from $CNTA. The portfolio is most concentrated in Healthcare (97.5% of disclosed assets). All figures are sourced directly from Spruce Street Capital LP’s Form 13F-HR filing with the SEC under CIK 2050194.

Funds like this

managers whose biggest positions overlap Spruce Street Capital's
Commodore Capital LP$1.68B 13F book · 14 shared top holdingsRLAYALKSANROELVNTCG Crossover Management, LLC$4.16B 13F book · 10 shared top holdingsDNTHRLAYSVRALBRXVivo Capital, LLC$1.10B 13F book · 10 shared top holdingsDNTHANROLBRXNERVVR Adviser, LLC$3.30B 13F book · 10 shared top holdingsDNTHSVRAERASRLMDStemPoint Capital LP$580.52M 13F book · 9 shared top holdingsDNTHELVNKNSAALKSDeep Track Capital, LP$6.87B 13F book · 4 shared top holdingsPCVXALKSALMSLBRX

Browse Top Institutional Investors

13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.

Berkshire HathawayBridgewater AssociatesCitadel AdvisorsRenaissance TechnologiesTwo Sigma InvestmentsDE Shaw & CoMillennium ManagementAQR Capital ManagementPoint72 Asset ManagementTiger Global ManagementVanguard GroupBlackRock

to search all 8,700+ institutional filers.

AI-Powered Hedge Fund Analysis: Spruce Street Capital LP

13F Pro is an AI hedge fund tracker and stock research platform. For Spruce Street Capital LP (SEC CIK: 2050194), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.

Every holding in Spruce Street Capital LP's portfolio is scored on an AI quality ranking built from its SEC filings (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.